CASC3 and Miyoshi myopathy: Taken together, our results indicate that BCMA-BTZ-NPs are a more efficient ICD inducer than free BTZ, acting not only as a targeted therapeutic agent but also as a modulator of anti-tumor immune response in MM (Fig. 8, schema).